Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 3/20 | 0.45 |
| ▸ | KDM1A | O60341 | 4/20 | 0.40 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5395926 | 1.00 | SRD5A1 (0.45) | SRD5A1KDM1AKDM1BIDO1CYP17A1 | |
| SCHEMBL30468607 | 1.00 | SRD5A1 (0.45) | SRD5A1KDM1AKDM1BIDO1CYP17A1 | |
| SCHEMBL29809159 | 1.00 | SRD5A1 (0.45) | SRD5A1KDM1AKDM1BIDO1CYP17A1 | |
| SCHEMBL2242353 | 1.00 | SRD5A1 (0.45) | SRD5A1KDM1AKDM1BIDO1CYP17A1 | |
| Hydrochloric Acid SCHEMBL26962651 | 0.98 | SRD5A1 (0.44) | SRD5A1KDM1AKDM1BIDO1CYP17A1 | |
| Hydrochloric Acid SCHEMBL30468609 | 0.98 | SRD5A1 (0.44) | SRD5A1KDM1AKDM1BIDO1CYP17A1 | |
| Hydrochloric Acid SCHEMBL17579695 | 0.98 | SRD5A1 (0.44) | SRD5A1KDM1AKDM1BIDO1CYP17A1 | |
| Hydrochloric Acid SCHEMBL6932003 | 0.98 | SRD5A1 (0.44) | SRD5A1KDM1AKDM1BIDO1CYP17A1 | |
| Methylamine SCHEMBL27768740 | 0.96 | SRD5A1 (0.47) | SRD5A1KDM1AKDM1BIDO1CYP17A1 | |
| SCHEMBL18289385 | 0.89 | KDM1A (0.42) | SRD5A1KDM1AKDM1BCYP17A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099936-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-04-12 | — | — | US | claimed |
| US-9856220-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-01-02 | — | — | US | claimed |
| EP-2780324-B1 | HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-05-17 | — | — | EP | claimed |
| US-20160318871-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. | 2016-11-03 | — | — | US | claimed |
| US-20130116229-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2013-05-09 | — | — | US | claimed |
| EP-0538134-B1 | Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase | TEVA PHARMA (IL) | 1997-03-12 | — | — | EP | claimed |
| CN-1073427-A | Phenyl ring list fluorizated N-propargyl-1-aminoidan reaches the selective depressant as monoamine oxidase (MAO) | TEVA PHARMA (IL) | 1993-06-23 | — | — | CN | claimed |
| EP-0538134-A2 | Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1993-04-21 | — | — | EP | claimed |
| US-12630516-B2 | Compounds | NRG THERAPEUTICS LTD. (GB) | 2026-05-19 | — | — | US | disclosed |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12497359-B2 | Acrylamide derivatives | NRG THERAPEUTICS LTD (GB) | 2025-12-16 | — | — | US | disclosed |
| EP-4208442-B1 | MPTP INHIBITORS | NRG THERAPEUTICS LTD (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| WO-2000069816-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2000-11-23 | — | — | WO | disclosed |
| CN-1038928-C | Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase | TEVA PHARMA (NL) | 1998-07-01 | — | — | CN | disclosed |
| EP-0538134-B1 | Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase | TEVA PHARMA (IL) | 1997-03-12 | — | — | EP | disclosed |
| US-5486541-A | FOR TREATING PARKINSON*S DISEASE, MEMORY DISORDERS, ALZHEIMER*S DISEASE, DEPRESSION OR HYPERACTIVE SYNDROME | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-01-23 | — | — | US | disclosed |
| CN-1073427-A | Phenyl ring list fluorizated N-propargyl-1-aminoidan reaches the selective depressant as monoamine oxidase (MAO) | TEVA PHARMA (IL) | 1993-06-23 | — | — | CN | disclosed |
| EP-0538134-A2 | Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630516-B2 | Compounds | CYP4B1, CYP1B1, NR4A1 | SRD5A1 161/4885KDM1A 1044/4885KDM1B 1240/4885 |
| US-20160318871-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE3A, PDE5A, PDE3B | SRD5A1 98/4885KDM1A 991/4885KDM1B 1557/4885 |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | ACR, CCNI, FANCI | SRD5A1 1388/4885KDM1A 3849/4885KDM1B 4281/4885 |
| US-20130116229-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE7A, PDE5A, PDE2A | SRD5A1 524/4885KDM1A 518/4885KDM1B 1066/4885 |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC3, HDAC1 | SRD5A1 184/4885KDM1A 1332/4885KDM1B 914/4885 |
| US-12497359-B2 | Acrylamide derivatives | ACR, GSTA2, GSTA1 | SRD5A1 1357/4885KDM1A 3893/4885KDM1B 4394/4885 |
| US-20180099936-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE3A, PDE5A, PDE3B | SRD5A1 100/4885KDM1A 964/4885KDM1B 1538/4885 |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | SRD5A1 2473/4885KDM1A 1023/4885KDM1B 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.